QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
NASDAQ:CMPS

COMPASS Pathways (CMPS) Stock Price, News & Analysis

$8.50
-1.00 (-10.53%)
(As of 12:04 PM ET)
Today's Range
$8.30
$9.35
50-Day Range
$8.03
$12.37
52-Week Range
$5.01
$12.75
Volume
1.36 million shs
Average Volume
685,025 shs
Market Capitalization
$526.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.00

COMPASS Pathways MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
463.2% Upside
$49.00 Price Target
Short Interest
Healthy
5.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of COMPASS Pathways in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.06 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.45) to ($2.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.92 out of 5 stars

Medical Sector

471st out of 939 stocks

Pharmaceutical Preparations Industry

220th out of 434 stocks

CMPS stock logo

About COMPASS Pathways Stock (NASDAQ:CMPS)

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CMPS Stock Price History

CMPS Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Mental Health Mavericks: 3 Stocks Changing the Game
CMPS Mar 2024 10.000 call
COMPASS Pathways plc (CMPS)
See More Headlines
Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CMPS
Fax
N/A
Employees
186
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$49.00
High Stock Price Target
$120.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+415.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-118,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.65 per share

Miscellaneous

Free Float
47,083,000
Market Cap
$588.43 million
Optionable
Optionable
Beta
2.52

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. George Jay Goldsmith (Age 69)
    Chairman & Co-founder
    Comp: $826.37k
  • Mr. Kabir Nath M.A. (Age 60)
    M.B.A., CEO & Director
    Comp: $952.19k
  • Dr. Ekaterina Malievskaia M.D. (Age 58)
    Co-Founder & Director
    Comp: $567.91k
  • Mr. Matthew Allen Owens (Age 47)
    General Counsel & Chief Legal Officer
    Comp: $659.53k
  • Ms. Teri Loxam M.B.A. (Age 51)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Greg Ryslik Ph.D.
    Chief Technology Officer
  • Mr. Stephen D. Schultz
    Senior Vice President of Investor Relations
  • Mr. Christopher Williams
    Chief Communications Officer
  • Ms. Anne Benedict
    Chief People Officer
  • Mr. Lars Christian Wilde (Age 39)
    Senior Advisor

CMPS Stock Analysis - Frequently Asked Questions

Should I buy or sell COMPASS Pathways stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPS shares.
View CMPS analyst ratings
or view top-rated stocks.

What is COMPASS Pathways' stock price target for 2024?

5 brokerages have issued 1 year price objectives for COMPASS Pathways' stock. Their CMPS share price targets range from $16.00 to $120.00. On average, they expect the company's stock price to reach $49.00 in the next year. This suggests a possible upside of 463.2% from the stock's current price.
View analysts price targets for CMPS
or view top-rated stocks among Wall Street analysts.

How have CMPS shares performed in 2024?

COMPASS Pathways' stock was trading at $8.75 on January 1st, 2024. Since then, CMPS stock has decreased by 0.6% and is now trading at $8.70.
View the best growth stocks for 2024 here
.

Are investors shorting COMPASS Pathways?

COMPASS Pathways saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 3,150,000 shares, a decline of 15.8% from the February 29th total of 3,740,000 shares. Based on an average daily trading volume, of 680,400 shares, the days-to-cover ratio is presently 4.6 days.
View COMPASS Pathways' Short Interest
.

When is COMPASS Pathways' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CMPS earnings forecast
.

How were COMPASS Pathways' earnings last quarter?

COMPASS Pathways plc (NASDAQ:CMPS) released its quarterly earnings results on Thursday, February, 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.16.

What ETFs hold COMPASS Pathways' stock?

ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).ARK Genomic Revolution ETF (ARKG).

What other stocks do shareholders of COMPASS Pathways own?

Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and

When did COMPASS Pathways IPO?

COMPASS Pathways (CMPS) raised $100 million in an initial public offering on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are COMPASS Pathways' major shareholders?

COMPASS Pathways' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (4.23%), Affinity Asset Advisors LLC (0.89%), Barclays PLC (0.81%), Sumitomo Mitsui Trust Holdings Inc. (0.59%), Nikko Asset Management Americas Inc. (0.59%) and PFM Health Sciences LP (0.55%). Insiders that own company stock include David Y Norton, Ekaterina Malievskaia and George Jay Goldsmith.
View institutional ownership trends
.

How do I buy shares of COMPASS Pathways?

Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners